MANGOCEUTICALS, INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash equivalents | $58,653 | $739,006 |
| Inventory | - | 18,501 |
| Prepaid expenses - related party | - | 60,953 |
| Deposits | 16,942 | 16,942 |
| TOTAL CURRENT ASSETS | 75,595 | 835,402 |
| NON-CURRENT ASSETS | ||
| Property and equipment, net of accumulated depreciation of $2,256 and $28,752 | 2,806 | 96,129 |
| Right of use - asset | 59,493 | 119,262 |
| Intangible assets - acquired patents, net of amortization | 15,232,617 | - |
| TOTAL NON-CURRENT ASSETS | 15,294,916 | 215,391 |
| TOTAL ASSETS | $15,370,511 | $1,050,793 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | 837,501 | 140,765 |
| Payroll tax liabilities | - | 6,595 |
| Notes payable | 150,000 | - |
| Right-of-use liability - operating lease | 64,962 | 63,718 |
| Other liabilities - patent purchase payable | 373,000 | - |
| TOTAL CURRENT LIABILITIES | 1,425,463 | 211,078 |
| LONG-TERM LIABILITIES | ||
| Right-of-use liability - operating lease | - | 64,961 |
| TOTAL LONG-TERM LIABILITIES | - | 64,961 |
| TOTAL LIABILITIES | 1,425,463 | 276,039 |
| COMMITMENTS AND CONTINGENCIES (SEE NOTE 11) | - | - |
| STOCKHOLDERS’ EQUITY | ||
| Series B Convertible Preferred stock, (par value $0.0001), 6,000 shares authorized, 2,770 and 0 shares were issued and outstanding as of December 31, 2024 and 2023, respectively | - | - |
| Series C Convertible Preferred stock (par value $0.0001), 6,250,000 shares authorized 980,000 and 0 shares were issued and outstanding as of December 31, 2024 and 2023, respectively | 98 | - |
| Common stock (par value $0.0001), 200,000,000 shares authorized, of which 3,245,641 and 1,427,967 shares issued and outstanding as of December 31, 2024 and 2023, respectively)* | 325 | 148 |
| Stock warrants | 324,288 | - |
| Subscription receivable | (1,150,000) | - |
| Additional paid in capital | 35,587,858 | 12,002,779 |
| Accumulated deficit | (20,806,595) | (11,228,173) |
| Accumulated other comprehensive loss | (9,845) | - |
| TOTAL STOCKHOLDERS’ EQUITY | 13,946,129 | 774,754 |
| Non-controlling interest | (1,081) | - |
| TOTAL STOCKHOLDERS’ EQUITY | 13,945,048 | 774,754 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $15,370,511 | $1,050,793 |
| * | Shares have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 15 reverse stock split |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.